Correlation between Long-Term Aspirin Use and F-Fluorodeoxyglucose Uptake in Colorectal Cancer Measured by PET/CT

Binbin Su1, Baixuan Xu2*, Jun Wan1*

1 Department of Gastroenterology, South Building, Chinese PLA General Hospital, Beijing, China, 2 Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing, China

Abstract

Purpose: The aim of this study was to evaluate the relationship between long-term aspirin use with pretreatment 18 Fluorodeoxyglucose (FDG) uptake of primary lesions of Colorectal cancer (CRC) and evaluate their clinical significance.

Materials and Methods: We enrolled 84 patients with CRC who underwent 18F-FDG PET/CT scanning before surgery between 1st July 2008 and 1st March 2013 and followed up until 1st March 2014. Maximum standardized uptake value (SUVmax) of the primary tumor was measured by 18F-FDG PET/CT. The history of aspirin taken and other clinicopathological factors were also obtained and their relationships were examined by Mann-Whitney or χ2 tests. Progression-free survival (PFS) was determined by standard Kaplan-Meier survival analysis. Cox proportional hazards regression was performed to determine whether history of aspirin taken, pretreatment SUVmax, age, gender, TNM stage, tumor sizes and differentiation influenced outcomes.

Results: CRC Patients with long-term history of aspirin use had lower SUVmax of primary lesions than control group (9.74 ± 2.62 vs. 13.91 ± 6.18) and showed a trend towards improved PFS after curative surgery. However, pretreatment of SUVmax showed no prognostic value in patients with CRC.

Conclusions: Long-term aspirin use is associated with lower pretreatment SUVmax of CRC and is a promising prognostic factor for predicting PFS in patients with CRC.

Introduction

Colorectal cancer (CRC) is the third most common cancer in the world, accounting for more than 1.2 million new cases diagnosed and 600,000 deaths annually [1]. There is a substantial body of epidemiological evidence indicating that regular use of aspirin is associated with a reduced risk of CRC-specific mortality [2]. More recently, a meta-analysis of five large cardiovascular trials provides proof-of-principle that aspirin is able to reduce distant cancer metastasis [3]. However, the mechanism of action of the CRC chemopreventive and anticancer effects of aspirin is not fully understood and debatable [4].

Biological imaging by positron emission tomography (PET) using 18F-2-fluoro-2-deoxy-D-glucose (FDG) has been widely used clinically for the detection of primary tumors and for early prediction of response to chemotherapy [5]. Given the known biological characters of tumors, 18F-FDG accumulation in tumors is used as index of increased glucose uptake and as a marker of tumor proliferation and metastatic potential, and recent investigations demonstrate the usefulness as a prognosticator for eventual outcomes [6,7,8].

Consistent with experimental evidence in animals that aspirin can impair glucose transport in tumor cells by targeting the pivotal glucose transporter GLUT1 [9], which is directly involved in FDG uptake, we therefore hypothesized that long term aspirin use may mediate changes of CRC biological characteristic which could be evaluated by FDG uptake. Based on that, this study was initiated to evaluate FDG uptake of CRC patients with long-term history of aspirin use and determined whether metabolic activity is correlated with recurrence and progression-free survival.

Materials and Methods

Patients

This study was approved by the Institutional Review Board of Chinese PLA General Hospital, and the requirement of informed consent was waived due to the retrospective nature of this study. From 1st July 2008 and 1st March 2013, patients that presented to
our institution with the initial diagnosis of CRC and were submitted to a curative CRC resection were retrospectively reviewed. Patients recruitment criteria included: 1) patients had a baseline PET/CT scan within 2 weeks prior to surgery, 2) they had radical surgery with stage I to III, 3) they did not received any neoadjuvant chemotherapy or radiation therapy before undergoing 18F-FDG PET or surgery. The pathological stage of the disease was based on the pathology reports from the definitive surgery in all cases. From the medical records, the history of aspirin use was documented. The patients were divided into two groups. The patients who have regular aspirin taken for at least 5 years with doses of at least 75 mg daily comprised the aspirin group, while the patients who never or occasionally take aspirin were comprised the control group.

PET/CT acquisition and analysis

All subjects underwent PET/CT scans using 18F-FDG within 2 weeks before surgery with the protocol of PET/CT scanning used at our institution. Before imaging, patients fasted for 6 h and their blood glucose levels were as tested, below 7 mmol/L. The recommended intravenously injected dosage for 18F-FDG was 5.55 MBq/kg and a standard 60 min post-injection rest allowed before PET/CT scanning. FDG-PET/CT scans were performed on a PET/CT scanner (Biograph Truepoint, Siemens). The data acquisition procedures were as follows: The scan covered the trunk from skull base to midtigh. Attenuation correction was performed using a low-dose helical CT protocol (90 mAs, 110 kV, 0.9 pitch) under normal breathing. Immediately after CT scanning, a PET emission scan that covered the identical transverse field of view was obtained. The PET images, including axial, sagittal and coronal images, were reconstructed using the true X method, and postfiltered with a 5.0 mm full width at half maximum (FWHM) in a matrix of 168. SUV $= (activity/unit volume)/(injected dose/total body weight)$. The maximum SUV (SUV max) was defined as the peak SUV on one pixel with the highest counts within region of interest. Images of PET/CT were reviewed by two nuclear medicine doctors experienced in PET/CT image reading.

Histological analysis and outcome evaluation

All surgical specimens were diagnosed by one experienced pathologist, and the longest diameter reported by the pathologist was used as the tumor size in this analysis. Tumor-related parameters were collected including p-T stage, p-N status, tumor size, and histopathological findings.

After curative resection of the tumor, adjuvant chemotherapy or chemoradiotherapy were indicated for all patients with lymph node-positive colorectal cancer. All patients had follow-up examinations approximately every 3 months for the first year, every 6 months for the next 2 years, and every 1 year thereafter. Tumor recurrence was confirmed by either tissue biopsy or the demonstration of progressive disease by serial imaging methods. Clinical proofs of no recurrent disease consisted of a negative physical and examination, negative tissue biopsy, and negative findings on serial follow-up imaging methods.

Statistical analysis

Group means were compared using the Mann-Whitney or $\chi^2$ tests. Progression-free survival was defined as the time to a specified recurrence and was measured from the day of surgery. Progression-free survival (PFS) was determined by standard Kaplan-Meier survival analysis, and between-group comparison was performed by log-rank test. Hazard ratios (HR) were derived from Cox regression analysis. All statistics were completed using SPSS version 20 (IBM Corp, Armonk, NY). A P-value less than 0.05 was considered statistically significant.

Results

Patient characteristics

There were a total of 1023 cases with CRC who were diagnosed and treated in the authors’ institution between 1st July 2008 and 1st March 2013. Eighty-four patients with a median age 72 years (range: 32–89 years) were identified. The baseline characteristics of the patients are shown in Table 1. Sixty two (73.8%) patients were male. Aspirin group comprised 23.3% of patients. All of those 20 patients took aspirin at dose of 100 mg per day for CV disease prevention. The pretreatment maximum SUV ranged from 4.9 to 32.0 with median value of 13.0. There were no statistically significant differences between the aspirin and control groups with respect to any of clinicopathological factors.

The association between Long term aspirin use and SUV max

Detailed results for the relationships between 18F-FDG uptake and clinicopathological factors are shown in Table 2. Long term aspirin use was found to have a significant relationship with 18F-FDG uptake ($P = 0.04$). Lower 18F-FDG uptake was observed in aspirin group compared with control group, with statistically significant differences in SUV max. In addition, High p-T stage ($P = 0.02$) and large tumor sizes ($P = 0.02$) were associated with increases in SUV max. Finally, there were no statistically significant differences in SUV max in terms of other histopathological findings. Gender, age (<60 years versus ≥60 years), p-N status, and differentiation were not associated with the SUV max.

Long term aspirin use as a predictor of survival

Based on the SUV max cutoff value of 13.0 (4.9–32.0), patients were divided into a high SUV max group (SUV max ≥ 13.0; n = 37) or a low SUV group (SUV max < 13.0, n = 47). The median follow-up was 52.7 months (range 0.7–70.3). During this period, 21 patients showed recurrent disease, of which 13 patients had distant metastases, 4 patients had both local and distant recurrence, 4 patients died from cancer-related causes.

Aspirin group had a statistically significant improvement in PFS compared to control group. The corresponding 2-year probability of PFS was 94% and 73%, respectively (Fig. 1). In contrast, SUV max showed no significant association with PFS ($P = 0.11$).

In the univariate analysis (Table 3), N stage and tumor differentiation showed a significant associations with PFS ($P = 0.005$, $P = 0.002$, respectively). However, long term history of aspirin use also showed a trend towards improved PFS ($P = 0.06$). At multivariate analysis, including N stage, aspirin use history and tumor differentiation, only N stage showed a prognostic significance ($P = 0.04$).

Discussion

Epidemiological studies have provided information on the chemopreventive effect of aspirin against CRC [10]. However, the optimal dose and duration of aspirin is not known. On the basis of current evidence, it can be assumed that regular dose of aspirin (75 mg–300 mg) taken over a 5-year period in patients will probably confer substantial CRC-specific survival benefit [11]. Thus, in this study, we identified aspirin group as the patients who have at least 5-year history of aspirin use at dose of 75 mg–300 mg daily.
To our knowledge, no research has been conducted on the relationship between aspirin use and FDG uptake in CRC. However, the interest in FDG-PET to assess the response of tumor to chemotherapy began in the early 1990s [12]. Previous studies have already shown that the degree of chemotherapy-induced metabolic changes in tumors is highly predictive of patient outcome [13,14]. In the past 5 years, multiple lines of evidence indicate that regular aspirin use can reduce CRC-specific mortality [15,16,17]. However, aspirin show no demonstrable activity in patients with overt metastatic cancer [18,19]. Further-

### Table 1. Patient demographics and clinical characteristics.

| Characteristic          | Aspirin group n = 20 | Control group n = 64 | P-value |
|-------------------------|----------------------|----------------------|---------|
| Age (y)                 | 75.2±9.87            | 71.7±13.8            | 0.30    |
| Gender                  |                      |                      |         |
| Male                    | 16(80%)              | 46(71.9%)            | 0.47    |
| Female                  | 4(20%)               | 18(28.1%)            |         |
| Tumor sizes (cm)        | 4.26±1.80            | 4.87±2.16            | 0.25    |
| Differentiation         |                      |                      |         |
| Well                    | 15(75%)              | 51(79.7%)            | 0.65    |
| Poor                    | 5(25%)               | 13(20.3%)            |         |
| T classification        |                      |                      |         |
| T1+T2                   | 4(20%)               | 13(20.3%)            | 0.97    |
| T3+T4                   | 16(80%)              | 51(79.7%)            |         |
| N classification        |                      |                      |         |
| N0                      | 13(65%)              | 43(67.2%)            | 0.85    |
| N1+N2                   | 7(35%)               | 21(32.8%)            |         |
| Pretreatment SUV max    | 9.74±2.62            | 13.91±6.18           | 0.004   |
| Dose of aspirin (mg/d)  | 100                  | 0                    |         |

doi:10.1371/journal.pone.0109459.t001

### Table 2. Clinicopathological implication of Pretreatment SUVmax combination status.

| Characteristic          | No. of patients | Pretreatment SUVmax | P-value |
|-------------------------|-----------------|---------------------|---------|
| Age (y)                 |                 |                     |         |
| <60                     | 14              | 14.0±5.56           | 0.4     |
| ≥60                     | 70              | 12.6±5.87           |         |
| Gender                  |                 |                     |         |
| Male                    | 62              | 13.2±6.45           | 0.4     |
| Female                  | 22              | 12.0±3.35           |         |
| Tumor sizes (cm)        |                 |                     |         |
| <5                      | 49              | 11.2±5.03           | 0.02    |
| ≥5                      | 35              | 15.2±6.12           |         |
| Differentiation         |                 |                     |         |
| Well                    | 66              | 12.78±5.73          | 0.67    |
| Poor                    | 18              | 13.4±6.24           |         |
| T classification        |                 |                     |         |
| T1+T2                   | 17              | 10.1±4.17           | 0.02    |
| T3+T4                   | 67              | 13.63±5.97          |         |
| N classification        |                 |                     |         |
| N0                      | 56              | 13.5±6.26           | 0.17    |
| N1+N2                   | 28              | 11.7±4.65           |         |
| Aspirin use             |                 |                     |         |
| Yes                     | 20              | 9.74±2.62           | 0.04    |
| No                      | 64              | 13.91±6.18          |         |

doi:10.1371/journal.pone.0109459.t002
more, in a recent large population-based cohort, low-dose aspirin usage after diagnosis of CRC did not increase survival time [20]. The differential effects of aspirin before and after diagnosis of CRC probably indicated that long term use of aspirin before diagnosis may mediate tumor biological changes to less aggressive type, which may be evaluated by the SUV in FDG-PET. In an attempt to throw some light on this, we conducted our survey.

In the present study, SUV max was significantly related to tumor size and depth of invasion, which is in agreement with most clinical studies on various malignancies, such as colon cancer [21], pancreas cancer [22] and breast cancer [23]. More important, according to our data, long term aspirin use before diagnosis of CRC is negatively correlated with FDG uptake of primary lesions and showed significant improvement in PFS.

As known, FDG uptake is used as index of increased glucose metabolism and as a marker of tumor viability for which, the degree of FDG uptake presumed to reflect tumor aggressiveness [24,25,26]. Several studies have demonstrated that FDG uptake is an indirect reflection of tumor hypoxia [27]. Hypoxia renders tumor cells more invasive phenotype and less susceptible to radiotherapy and chemotherapeutic agents [28,29]. This is substantiated by clinical studies which revealed that tumor hypoxia is associated with poor disease-free and overall survival rates in several types of cancer [30]. FDG also reflect tumor differentiation [31] and genetic mutation status [32]. In a study focusing on CRC, SUV on pre-treatment F-18 FDG-PET/CT could be used as a good surrogate marker for the prediction of disease progression [33]. Therefore, FDG uptake is now considered to be a useful surrogate in-vivo biomarker in the staging, predicting tumor aggressiveness and treatment outcome.

Although direct effect of aspirin on FDG uptake is still an unexplored preposition, emerging evidence indicated that aspirin is involved in shaping tumor microenvironment which may have an impact on FDG uptake [34]. As known, aspirin inhibits both COX-1 and COX-2; but it preferentially inhibits COX-1. Because platelets have a limited capacity to generate COX-1 de novo [35], the oral administration of aspirin at low-dose, once daily causes an almost complete suppression of platelet COX-1 [36]. On the contrary, very high doses of aspirin (>1000 mg), do achieve sufficient systemic concentrations to inhibit COX-2 activity [37], and this inhibition can only be maintained by repeated dosing three or four times daily [38]. In addition, higher dose of aspirin do not further improve CRC survival [39]. The finding of aspirin benefit at low dose in cancer prevention, locates the antiplatelet effect of aspirin at the center of its antitumor efficacy. To date, at least 20 angiogenic-regulating factors have been identified in

Table 3. Univariate and multivariate analysis of prognostic factors of PFS.

| Characteristic | Univariate analysis | Multivariate analysis |
|---------------|---------------------|----------------------|
|               | HR 95%CI P          | HR 95%CI P           |
| Age (<60 vs ≥60) | 0.45 0.21–1.97 0.453 | 0.45 0.21–1.97 0.453 |
| Gender (M vs F) | 0.65 0.23–1.81 0.414 | 0.65 0.23–1.81 0.414 |
| Sizes (<5 cm vs ≥5 cm) | 0.871 0.38–2.25 0.929 | 0.871 0.38–2.25 0.929 |
| Dif (well vs poor) | 4.121 1.66–10.194 0.002 | 2.47 0.914–6.689 0.075 |
| T (T1+2 vs T3+4) | 1.624 0.476–5.548 0.439 | 1.624 0.476–5.548 0.439 |
| N (N0 vs N1+N2) | 3.578 1.45–8.77 0.005 | 2.696 1.008–7.209 0.048 |
| Aspirin (yes vs no) | 4.10 0.945–17.82 0.06 | 3.58 0.81–5.884 0.093 |
| SUVmax (<13 vs ≥13) | 2.061 0.822–5.17 2.06 | 2.061 0.822–5.17 2.06 |

doi:10.1371/journal.pone.0109459.t003
platelets, such as platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), angiostatin and insulin-like growth factor (IGF), including both pro-and anti-angiogenic factors [40]. Excess production of proangiogenic factors and/or diminished production of anti-angiogenic factors are considered responsible of tumor vascular abnormality and hostility of tumor microenvironment [41,42]. Restoration of pro-and anti-angiogenic balance in tumors may “normalize” tumor vasculature and thus indirectly reduce the hostility of TME [43]. Given an abundant array of positive and negative angiogenesis regulators contained in platelets, platelets may have capacity to stimulate every stage of tumor angiogenesis and to shape TME. In fact, a recently study directly demonstrated that aspirin alter tumor microenvironment in T-cell lymphoma mouse model, which showed that oral administration of aspirin to mice as a prophylactic measure was accompanied by alterations in the biophysical, biochemical and immunological composition of the tumor microenvironment with respect to PH, level of dissolved O2 and glucose [44].

In present study, we found aspirin’s ability to decrease the SUV max of primary CRC lesions, while demonstrated no prognostic information from SUVmax of the primary lesions. Despite some researchers have suggested that FDG-PET have prognostic value for some types of malignancies [45,46,47], past studies were mainly focused on stage IV CRC [48]. Our study included only resectable CRC and is consistent with results from Lee,JE [49]. Use of aspirin prior to diagnosis was found to be associated with earlier tumor stage for CRC [50,51], however, it was beyond the scope of this study to assess whether long term use of aspirin provides a favorable impact on the staging characteristics of CRC. The main prognostic factors in this study for PFS were tumor stage, especially nodal stage.

There are some limitations in this study: first, the size of this study was relatively small. This was due to the fact that PET/CT scanning before CRC surgery is not the protocol in our institution; second, the duration of follow-up was relatively short. However, a recent analysis showed that most relapses occur within 2 years of surgery. Third, immunohistochemical information on glucose metabolism in colorectal cancer was unavailable. Therefore, a biological explanation for the correlation between aspirin and FDG accumulation and the behavior of the tumor was not suggested.

Conclusion

In conclusion, this study is a relatively small analysis, but highlights the fact that FDG accumulation in primary CRC with long term aspirin use is significantly lower than in those without aspirin use. Although the larger number of patients is needed, these results indicate that aspirin may mediate changes of CRC biological characteristic. Thus, this study provides a novel possibility of FDG-PET/CT scans to be used for noninvasive evaluation for cancer prevention strategies. To validate this idea, further prospective studies with a larger number of patients and clinical follow-up are needed. Furthermore, it should be investigated whether FDG-PET/CT scans might predict the actual response to aspirin as well as survival rates.

Author Contributions

Conceived and designed the experiments: JW. Performed the experiments: BS. Contributed reagents/materials/analysis tools: BS BX. Contributed to the writing of the manuscript: BS.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
2. McCowan C, Munro AJ, Doman PT, Steele RJ (2013) Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 49: 1049–1057.
3. Rothwell PM, Wilson M, Price JF, Bleif RL, Meade TW, et al. (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379: 1591–1601.
4. Syneonidou D, Koukoulis G, Christosdoulidou G, Mamaloukis I, Chatzinikolaou L, et al. (2012) Impact of antiplatelet treatment on colorectal cancer staging characteristics. World J Gastroenterol 4: 409–413.
5. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, et al. (2005) Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11: 2583–2598.
6. Hong D, Lunagomeosa S, Kim EE, Lee JH, Bresalier RS, et al. (2005) Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 104: 1629–1626.
7. Na, II, Byun BH, Kang HJ, Cheon GJ, Koh JS, et al. (2008) 18F-fluoro-2-deoxyglucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer. Clin Cancer Res 14: 2036–2041.
8. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, et al. (2004) The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45: 17–21.
9. Kumar A, Vishvakarma NK, Tyagi A, Bhati AC, Singh SM (2012) Antineoplastic action of aspirin against a T-cell lymphoma involves an alteration in the tumour microenvironment and regulation of tumor cell survival. Biochem Biophys Res Commun 32: 91–104.
10. Walker AJ, Grainge MJ, Card TR (2012) Aspirin and other non-steroidal anti-inflmmatory drug use and colorectal cancer survival: a cohort study. Br J Cancer 107: 1602–1607.
11. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, et al. (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376: 1741–1750.
12. Ichiya Y, Kowabara Y, Otsuka M, Tahara T, Yoshikai T, et al. (1991) Assessment of response to cancer therapy using fluore-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 32: 1655–1660.
13. de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermens R, van Houw BA, et al. (2008) Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 19: 348–352.
14. Findlay M, Young H, Cumming D, Iveson A, Cronin B, et al. (1996) Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 14: 700–708.
15. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, et al. (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101: 256–266.
16. Duhe C, Rostom A, Lewin G, Tserovzade A, Barrowman N, et al. (2007) The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146: 362–375.
17. McCowan C, Munro AJ, Doman PT, Steele RJ (2013) Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 49: 1049–1057.
18. Creagan ET, Twito DI, Johansson SL, Schaid DJ, Johnson PS, et al. (1991) A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma. J Clin Oncol 9: 2104–2109.
19. Lebeau B, Chatang C, Murn JiF, Vincent J, Massin F, et al. (1993) No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group. Cancer 71: 1741–1745.
20. Cardwell CR, Kumzmann AT, Cautwell MM, Hughes C, Barosa, et al. (2014) Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort. Gastroenterology 146: 700–708 e702.
21. Bystrom P, Burglund A, Garske U, Jacobsson H, Sundin A, et al. (2009) Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 20: 1057–1061.
22. Izushi K, Yamamoto Y, Sano T, Takebayashi R, Masaki T, et al. (2010) Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer. J Gastrointest Surg 14: 1151–1158.
23. Kenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, et al. (2007) Standardized uptake values for breast carcinomas assessed by fluorodeoxyglu-
Aspirin and F-Fluorodeoxyglucose Uptake in Colorectal Cancer

24. Furuta M, Hasegawa M, Hayakawa K, Yamakawa M, Ishikawa H, et al. (1997) Rapid rise in FDG uptake in an irradiated human tumour xenograft. Eur. J Nucl Med 24: 435–438.

25. Haberkorn U, Strauss LG, Reiser C, Haag D, Dimitrakopoulos A, et al. (1991) Glucose uptake, perfusion, and cell proliferation in head and neck tumours: relation of positron emission tomography to flow cytometry. J Nucl Med 32: 1548–1555.

26. Crippa F, Seregni E, Agresti R, Chiesa C, Pascale C, et al. (1998) Association between [18F] fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 25: 1429–1434.

27. Dierckx RA, Van de Wiele C (2000) FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging 35: 1544–1549.

28. Pennacchietti S, Michiel P, Galluzzo M, Mazzone M, Giordano S, et al. (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347–361.

29. Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG (2010) Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 177: 1491–1502.

30. Poon E, Harris AL, Ashcroft M (2009) Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med 11: e26.

31. Folpe AL, Lyles RH, Sprouse JT, Conrad EU, 3rd, Eary JF (2000) F-18 FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 41: 711–717.

32. Kumar A, Singh SM (2012) Priming effect of aspirin for tumor cells to augment cytotoxic action of cisplatin against tumor cells: implication of altered constitution of tumor microenvironment, expression of cell cycle, apoptosis, and survival regulatory molecules. Mol Cell Biochem 371: 43–54.

33. Evangelista V, Manarini S, Di Santo A, Capone ML, Ricciotti E, et al. (2006) De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 98: 593–595.

34. Patrignani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69: 1366–1372.

35. Rumble RH, Brooks PM, Roberts MS (1980) Metabolism of salicylate during chronic aspirin therapy. Br J Clin Pharmacol 9: 41–45.

36. Thun MJ, Jacobs EJ, Patrono C (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9: 259–267.

37. Chan AT, Arber N, Burn J, Chia WK, Ewood P, et al. (2012) Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) 5: 164–178.

38. Kalzirion-Balicka A, Moncada de la Rosa C, Jurase P (2012) Platelet-associated angiogenesis regulating factors: a pharmacological perspective. Can J Physiol Pharmacol 90: 679–688.

39. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 807–809.

40. Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG (2010) Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 177: 1491–1502.

41. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58–62.

42. Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG (2010) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347–361.

43. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 807–809.

44. Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG (2010) Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 177: 1491–1502.

45. Kato H, Nakajima M, Sohda M, Tanaka N, Inose T, et al. (2009) The clinical application of 18F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer 115: 3196–3203.

46. Hato R, Nakajima M, Sohda M, Tanaka N, Inose T, et al. (2009) The clinical application of 18F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer 113: 3196–3203.

47. Kato H, Nakajima M, Sohda M, Tanaka N, Inose T, et al. (2009) The clinical application of 18F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer 113: 3196–3203.

48. Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, et al. (2007) 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 48: 771–775.

49. Agresti R, Crippa F, Sandri M, Martelli G, Tagliabue E, et al. (2014) Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up. Breast 23: 354–360.

50. Cerfolio RJ, Bryan AS (2006) Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 82: 391–394; discussion 394–395.

51. Syneomidis D, Koukoulis G, Christodoulidis G, Mamaloudis I, Chatzinikolaou I, et al. (2012) Impact of antiplatelet treatment on colorectal cancer staging characteristics. World J Gastrointest Endosc 4: 409–413.